Clinical characteristics of TB to help advance novel therapies
The World Health Organization is publishing a position statement on Innovative Clinical Trial Designs for Development of New TB Treatments. This document aims to support TB regimen development by highlighting key clinical trial characteristics to help advance novel therapies. It summarizes key innovations in TB clinical trial designs, ranging from pharmacokinetic-pharmacodynamic (PK-PD) modelling and new advances in biomarker development to the value of novel clinical trial design methodologies and post-licensure observational studies.
The position statement targets TB drugs and regimens developers including pharmaceutical industry, TB researchers and trialists, preclinical scientists and modelers, and calls for increased collaboration as well as data sharing and integration and standardization of tools and measurements to advance scientific discovery. It also emphasizes engagement with national TB programs and affected communities to facilitate the translation of evidence into national and global policies on TB treatment and care.
Innovations in TB drug development and clinical trial design are anticipated to accelerate the development and evaluation as well as facilitate approval of novel regimens to treat all forms of TB and lead to a welcome expansion of the TB drug pipeline.
